William (Bill) Hahn, MD, PhD

William C. Hahn is a medical oncologist and Associate Professor in the Department of Medical Oncology at the Dana-Farber Cancer Institute and a Senior Associate Member of the Broad Institute of MIT and Harvard. He co-directs the Center for Cancer Genome Discovery, is the Chief of the Division of Molecular and Cellular Oncology and is the Deputy Chief Scientific Officer at the Dana-Farber Cancer Institute. In addition, he is a founding member of The RNAi Consortium, Broad Institute-based effort to develop genome scale RNA interference reagents and the technologies for their use.

William Hahn and his colleagues helped demonstrate that activation of the reverse transcriptase telomerase plays an essential role in malignant transformation. His current work focuses on the understanding the cooperative genetic interactions that lead to malignant transformation and the creation of novel experimental model systems for the study of normal and malignant epithelial biology. His laboratory has pioneered the use of integrated functional genomic approaches to identify and validate cancer targets.

Clinically, he is a member of the Lank Center for Genitourinary Oncology and is devoted to the development of new therapeutic strategies for the treatment of prostate and other cancers. As the co-director of the Center for Cancer Genome Discovery, he is committed to the development and implementation of technologies that permit the interrogation of cancer-associated mutations at genome scale and to implement these technologies prospectively in newly diagnosed patients.

William Hahn has been the recipient of many honors and awards including the 2000 Wilson S. Stone Award from M.D. Anderson Cancer Center for outstanding research in cancer, a Kimmel Scholar Award, the Howard Temin Award from the National Cancer Institute, an Award for Outstanding Research from Nature Biotechnology and the Ho-Am Prize in Medicine (2010).

William Hahn received his A.B. from Harvard University in Biochemical Sciences summa cum laude in 1987 and his M.D and Ph.D. from Harvard Medical School in 1994. He then completed clinical training in Internal Medicine at the Massachusetts General Hospital and Medical Oncology at the Dana-Farber Cancer Institute. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute for Biomedical Research and joined the faculty of DFCI and Harvard Medical School in 2001.

Back to scientific advisory board